No Data
No Data
Dongwu Securities released a research report on April 19 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) gross margin declined slightly due to changes in revenue structure; 2) the second grow
Dongwu Securities released a research report on April 19 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) gross margin declined slightly due to changes in revenue structure; 2) the second growth curve for the contact lens business opened; 3) Continued increase in R&D investment, and the clinical progress of new products is good. (Mainichi Keizai Shimbun)
Aibo Healthcare (688050): Performance exceeds expectations, contact lenses became the second growth curve
Introduction to this report: The company's 2024Q1 performance exceeded expectations. It is expected that the performance will grow steadily in the future, mainly due to the rapid increase in contact lenses and the release of profits due to the expansion of production lines and scale advantages. Key investment points: Maintain a prudent holdings increase rating. Khao
Aibo Healthcare (688050): Performance maintains rapid growth and rapid release of optometry products
Key investment results maintained rapid growth: the company released the 2023 annual report and the 2024 quarterly report, and achieved operating income of 951 million yuan in 2023 (+64%, year-on-year growth rate, same as below) and net profit of 3.04 million yuan to mother
Aibo Healthcare (688050) 23rd Annual Report and 24Q1 Quarterly Report Review: Revenue and Profit Increased in the First Quarterly Report; Contact Lens Business Expands Hyaluronic Acid into Clinical Practice
The annual report results are consistent with the express report: 1) In '23, the company achieved revenue of 951 million yuan/year on year +64.14%, with a return of 304 million yuan/year over year +30.63%, after deducting not 289 million yuan/year on year +38.96%
Cinda Securities released a research report on April 18 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) the annual report's performance is consistent with the quick report; 2) the quarterly r
Cinda Securities released a research report on April 18 stating that it gave Aibo Healthcare (688050.SH) a purchase rating. The main reasons for the rating include: 1) the annual report's performance is consistent with the quick report; 2) the quarterly report's revenue and profit increased; 3) the surgical business was booming domestically and rapidly expanded overseas in '23, and the national procurement is about to be implemented; 4) the contact lens business is the leader in the industry and has become the company's third growth curve; 5) continuous investment in R&D, and various key products are worth looking forward to. (Mainichi Keizai Shimbun)
Aibo Healthcare (688050): Mining implementation accelerates volume acquisitions to help business layout
Performance Overview On April 17, 2024, the company released its 2023 annual report. In 2023, the company achieved revenue of 951 million yuan (+64% year over year); realized net profit of 304 million yuan (+3 year over year)
No Data